Laura Sepp-Lorenzino, EVP, Chief Scientific Officer at Intellia Therapeutics, Inc. (NTLA), sold 51,874 shares at $135.47 ($7.2M) on 2021-08-04, disclosed to the SEC on 2021-08-06.
Open-market sale of $7.2M NTLA by EVP, Chief Scientific Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $135.47 | 1,471 | $199K | 2.8% |
| 2 | $135.47 | 1,471 | $199K | 2.8% |
| 3 | $136.79 | 6,814 | $932K | 13.0% |
| 4 | $136.79 | 6,814 | $932K | 13.0% |
| 5 | $137.72 | 6,344 | $874K | 12.2% |
| 6 | $137.72 | 6,344 |
| $874K |
| 12.2% |
| 7 | $138.78 | 4,419 | $613K | 8.6% |
| 8 | $138.78 | 4,419 | $613K | 8.6% |
| 9 | $139.85 | 2,772 | $388K | 5.4% |
| 10 | $139.85 | 2,772 | $388K | 5.4% |
| 11 | $140.73 | 4,054 | $571K | 8.0% |
| 12 | $140.73 | 4,054 | $571K | 8.0% |
| 13 | $141.63 | 126 | $18K | 0.2% |
| Total | $138.24 avg | 51,874 | $7.2M | 100% |
| Filing → |
| NTLA | SELL | 2024-01-05 | $326K | — | Filing → |
| NTLA | SELL | 2023-01-06 | $339K | — | Filing → |
| NTLA | SELL | 2022-03-03 | $129K | — | Filing → |